| 产品描述: | XS-060 is a potent anticancer agent and RXRα antagonist. XS-060 significantly induces RXRα-dependent mitotic arrest by inhibiting pRXRα-PLK1 interaction. XS-060 inhibits p-RXRα interaction with PLK1 but has no effect on RXRα heterodimerization with RARγ. XS-060 inhibits the in situ interaction between p-RXRα and PLK1 at the centrosome. |
| 体外研究: |
XS-060 (25 mg/kg, IP or PO, once) 腹腔注射吸收良好,但口服吸收很差。 |
| 体内研究: |
XS-060 靶向 RXRα' 的共激活因子结合位点可抑制 pRXRα-PLK1 相互作用,作为抗有丝分裂剂表现出良好的抗肿瘤活性。 XS-060 对 MDA-MB 231 癌细胞具有抗增殖活性,IC50 为 6.880 ± 0.059 μM。 |
| 参考文献: |
1. Chen J, et al. Discovery of bipyridine amide derivatives targeting pRXRα-PLK1 interaction for anticancer therapy. Eur J Med Chem. 2023 Apr 6;254:115341. 2. Xie G, et al. Centrosomal Localization of RXRα Promotes PLK1 Activation and Mitotic Progression and Constitutes a Tumor Vulnerability. Dev Cell. 2020 Dec 21;55(6):707-722.e9. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.991 ml |
14.953 ml |
29.907 ml |
| 5 mM |
0.598 ml |
2.991 ml |
5.981 ml |
| 10 mM |
0.299 ml |
1.495 ml |
2.991 ml |
| 50 mM |
0.06 ml |
0.299 ml |
0.598 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |